NKGen Biotech Inc (NKGN)

Why NKGen Biotech Stock Is Moving Higher Monday - NKGen Biotech (NASDAQ:NKGN) - Benzinga

Benzinga

NKGen Shares Soar After SNK01 Cleared for Phase 2 - MarketWatch

MarketWatch

NKGen Biotech's SNK01 NK Cell Therapy Cleared to Start - GlobeNewswire

GlobeNewswire

NKGen Biotech’s SNK01 NK Cell Therapy Cleared to Start Phase 2 Clinical Trial in Alzheimer’s Disease

GlobeNewswire Inc.

Midday Stock Roundup: Eledon, Avid Bioservices Up - Orange County Business Journal

Orange County Business Journal

Midday Stock Roundup: Eledon, Avid Bioservices Up - Orange County Business Journal

Orange County Business Journal

NKGen Biotech Announces Upcoming Presentation on Autologous NK Cell Therapy at the 5th International Cell ... - WICZ

WICZ

NKGen Biotech Announces Upcoming Presentation on Autologous NK Cell Therapy at the 5th International Cell ... - GlobeNewswire

GlobeNewswire

NKGen Biotech Announces Upcoming Presentation on Autologous NK Cell Therapy at the 5th International Cell & Gene Therapy China Summit & Exhibition

GlobeNewswire Inc.

NKGen Biotech gears up for Parkinson's trial after FDA nod By Investing.com - Investing.com

Investing.com

NKGen Biotech Presents Updated NK Cell Therapy Data for Neurodegenerative Disease at the 12th Annual Alzheimer’s & Parkinson’s Drug Development Summit

GlobeNewswire Inc.

NKGen Biotech Presents Updated NK Cell Therapy Data for Neurodegenerative Disease at the 12th Annual ... - GlobeNewswire

GlobeNewswire

NKGen Biotech Announces Upcoming Publication at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

GlobeNewswire Inc.

NKGN Stock Price and Chart — NASDAQ:NKGN — TradingView - TradingView

TradingView

What's Going On With Nano-Cap NKGen Biotech Stock On Monday? - Yahoo Finance

Yahoo Finance

NKGen Biotech Announces Upcoming Presentation on SNK01 NK Cell Therapy in Neurodegenerative Disease at the 12th Annual Alzheimer’s & Parkinson’s Drug Development Summit

GlobeNewswire Inc.

NKGen Biotech Announces Upcoming Presentation on SNK01 NK Cell Therapy in Neurodegenerative Disease at the ... - GlobeNewswire

GlobeNewswire

NKGen Biotech Secures $5M in Strategic Financing Deal - TipRanks.com - TipRanks

TipRanks

NKGen Biotech Secures Additional Financing of $5 Million to Continue Advancing Its Clinical Programs

GlobeNewswire Inc.

NKGen Biotech Secures Additional Financing of $5 Million to Continue Advancing Its Clinical Programs - GlobeNewswire

GlobeNewswire

NKGen Biotech Presents Additional Phase 1 Clinical Trial Data in Alzheimer’s Disease at the Tau2024 Global Conference

GlobeNewswire Inc.

NKGen Biotech Presents Additional Phase 1 Clinical Trial Data in Alzheimer's Disease at the Tau2024 Global ... - GlobeNewswire

GlobeNewswire

NKGen Biotech appoints new chairperson amid leadership shuffle - Investing.com Canada

Investing.com Canada

Trading Penny Stocks With $1,000, Top Tips

PennyStocks

Why United Natural Foods Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Benzinga

Why CrowdStrike Shares Are Trading Higher By Around 24%; Here Are 20 Stocks Moving Premarket

Benzinga

Why Is NKGen Biotech (NKGN) Stock Up 62% Today? - InvestorPlace

InvestorPlace

Why Paymentus Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket

Benzinga

NKGen Biotech Announces Upcoming Presentation on SNK01 in Alzheimer's Disease at the Tau2024 Global Conference - Yahoo Finance

Yahoo Finance

How to Use the Immune System Against Cancer and Alzheimer's, with Dr. Paul Song - upworthyscience.com

upworthyscience.com

NKGen Biotech Advances Alzheimer's Treatment with SNK01: First Patient Dosed in Phase 1/2a Trial - Yahoo Finance

Yahoo Finance

NKGen Biotech, Inc. Announces Dosing of First Patient in its Phase 1/2a Trial with Autologous NK Cell Product, SNK01, for the Treatment of Moderate Alzheimer’s Disease

GlobeNewswire Inc.

NKGen Biotech Announces Clearance of Clinical Trial Application by Health Canada for SNK01 NK Cell Therapy to Treat Alzheimer’s Disease

GlobeNewswire Inc.

NKGen Biotech Announces Clearance of Clinical Trial Application by Health Canada for SNK01 NK Cell Therapy to ... - Yahoo Finance

Yahoo Finance

NK Cell Therapy SNK01 Improves Cognitive Function in Alzheimer Disease for up to 11 Weeks - AJMC.com Managed Markets Network

AJMC.com Managed Markets Network

NKGen Biotech, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights - Yahoo Finance

Yahoo Finance

NKGen Biotech, Inc. Announces Closing of Business Combination - GlobeNewswire

GlobeNewswire

Graf Acquisition Corp IV (GFOR) Latest News & Price - InvestorPlace

InvestorPlace

NKGen doses the first patient in solid tumours therapy trial - Clinical Trials Arena

Clinical Trials Arena

Graf Acquisition Corp. IV and NKGen Biotech, Inc. Announce Effectiveness of Form S-4 for Proposed Business ... - GlobeNewswire

GlobeNewswire

NKMax submits US subsidiary's securities report to SEC - Korea Economic Daily

Korea Economic Daily

NKGen Biotech signs agreement to merge with Graf Acquisition - Pharmaceutical Technology

Pharmaceutical Technology

White & Case Advises Graf Acquisition Corp. IV on Business Combination with NkGen Biotech, Inc. - White & Case LLP

White & Case LLP

NKGen Biotech, Inc. to Become Publicly Traded Company via Business Combination with Graf Acquisition Corp. IV - GlobeNewswire

GlobeNewswire

S.Korean biotech NKMax’s unit aims for US IPO - Korea Economic Daily

Korea Economic Daily

NKGen Biotech Appoints Paul Y. Song, MD as Chief Executive Officer - GlobeNewswire

GlobeNewswire

Nkgen Biotech cleared to advance allogeneic NK cell therapy SNK-02 into clinic for solid tumors - BioWorld Online

BioWorld Online

NKGen Biotech Announces Appointment of Steven Cha, MD as Chief Medical Officer - GlobeNewswire

GlobeNewswire